Clinical trial · Interventional
Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer
Phase Ⅲ Study of Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer by Nadroparin
NCT01980849CI-TRIAL-00012707LCANunknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare the efficacy and safety of prophylaxis of venous thromboembolism by Nadroparin during hospitalization to long-term usage in patients with advanced lung cancer treated by chemotherapy and/or radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nadroparin, long term | Drug | — | UNRESOLVED |
| Nadroparin: short-term | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Long term prophylaxis
- description
- Nadroparin, 0.4mL, subcutaneously, qid, given by long-term
- interventionNames
- Drug: Nadroparin, long term
- type
- ACTIVE_COMPARATOR
- label
- Short-term prophylaxis
- description
- Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization
- interventionNames
- Drug: Nadroparin: short-term
Primary outcomes (1)
- measure
- Incidence of venous thromboembolism
- timeFrame
- 12 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Stage Ⅲ B and Ⅳ non-small cell lung cancer patients and inoperable small cell lung cancer patients * Performance status score ≤ 2 * Chest CT with measurable lesions Exclusion Criteria: * Examination revealed any part of venous thromboembolism * Chemotherapy regimens containing bevacizumab or Endostar * Severe coagulopathy * Active bleeding within two weeks
References
Publications (0)
Data not yet available
No reference posted for this study.